Table 3.
Pretreatment + treatment | Epithelial damage | Edema congestion | Polymorphonuclear leukocyte infiltration | Total score |
---|---|---|---|---|
Vehicle + vehicle control | 0.44 ± 0.1 | 0.97 ± 0.1 | 1.29 ± 0.2 | 2.73 ± 0.4 |
Vehicle + TxA | 1.61 ± 0.1a | 1.77 ± 0.1a | 1.90 ± 0.1 | 5.21 ± 0.2a |
FUT-175 + vehicle control | 1.02 ± 0.1 | 0.02 ± 0.1 | 0.88 ± 0.1 | 2.65 ± 0.2 |
FUT-175 + TxA | 1.03 ± 0.2a | 1.51 ± 0.2 | 1.77 ± 0.2 | 4.35 ± 0.3a |
MPI-0442352 + vehicle control | 0.56 ± 0.1 | 0.48 ± 0.02 | 0.56 ± 0.1 | 1.60 ± 0.2 |
MPI-0442352 + TxA | 1.67 ± 0.2 | 1.93 ± 0.2 | 1.98 ± 0.2 | 5.55 ± 0.5 |
10 mg SBTI + vehicle control | 0.30 ± 0.1 | 1.30 ± 0.1 | 1.46 ± 0.1 | 3.07 ± 0.2 |
10 mg SBTI + TxA | 0.53 ± 0.1b | 1.17 ± 0.3b | 1.63 ± 0.1 | 3.32 ± 0.3b |
20 mg SBTI + vehicle control | 0.43 ± 0.1 | 0.56 ± 0.1 | 0.79 ± 0.1 | 1.87 ± 0.2 |
20 mg SBTI + TxA | 0.86 ± 0.1b | 1.06 ± 0.1b | 1.24 ± 0.1 | 3.13 ± 0.3b |
NOTE. Vehicle refers to vehicle for protease inhibitors, and vehicle control refers to vehicle for TxA.
P < .05 compared with inhibitor vehicle + vehicle control group.
P < .05 compared with inhibitor vehicle + TxA group.